(0.80%) 5 169.02 points
(0.42%) 38 836 points
(0.88%) 16 298 points
(0.52%) $78.52
(2.57%) $2.20
(1.12%) $2 334.50
(3.62%) $27.66
(0.06%) $965.85
(-0.06%) $0.928
(-0.47%) $10.82
(-0.17%) $0.796
(-0.12%) $91.34
3 days till quarter result
(bmo 2024-05-09)
Expected move: +/- 3.14%
-0.09% INR 1 423.40
Live Chart Being Loaded With Signals
Cipla Limited, together with its subsidiaries, manufactures and sells pharmaceutical products in India, the United States, South Africa, and internationally...
Stats | |
---|---|
Объем за сегодня | 928 998 |
Средний объем | 1.49M |
Рыночная капитализация | 1 149.25B |
EPS | INR13.07 ( 2024-01-24 ) |
Дата следующего отчета о доходах | ( INR10.73 ) 2024-05-09 |
Last Dividend | INR8.50 ( 2023-07-20 ) |
Next Dividend | INR0 ( N/A ) |
P/E | 31.02 |
ATR14 | INR0.946 (0.07%) |
Объем Корреляция
Cipla Limited Корреляция
10 Самые положительные корреляции | |
---|---|
NESCO.NS | 0.972 |
SPENTEX.NS | 0.97 |
PODDARHOUS.NS | 0.967 |
HONAUT.NS | 0.965 |
INSECTICID.NS | 0.963 |
SHAILY.NS | 0.962 |
JINDALPOLY.NS | 0.96 |
AWHCL.NS | 0.957 |
ESTER.NS | 0.957 |
SETUINFRA.NS | 0.957 |
10 Самые отрицательные корреляции | |
---|---|
KIRLFER.NS | -0.948 |
JSLHISAR.NS | -0.937 |
CIGNITITEC.NS | -0.933 |
JINDALSAW.NS | -0.931 |
PGEL.NS | -0.925 |
SONATSOFTW.NS | -0.919 |
KAYNES.NS | -0.918 |
OIL.NS | -0.918 |
ISMTLTD.NS | -0.917 |
CLSEL.NS | -0.916 |
Вы знали?
Корреляция - это статистический показатель, описывающий связь между двумя переменными. Он изменяется от -1 до 1, где -1 указывает на идеальную отрицательную корреляцию (при увеличении одной переменной другая уменьшается), 1 указывает на идеальную положительную корреляцию (при увеличении одной переменной другая увеличивается), а 0 указывает на отсутствие корреляции (между переменными нет связи).
Корреляцию можно использовать для анализа связи между любыми двумя переменными, не только акциями. Она широко используется в таких областях, как финансы, экономика, психология и т. д.
Cipla Limited Корреляция - Валюта/Сырье
Cipla Limited Финансовые показатели
Annual | 2022 |
Выручка: | INR224.73B |
Валовая прибыль: | INR142.21B (63.28 %) |
EPS: | INR34.72 |
FY | 2022 |
Выручка: | INR224.73B |
Валовая прибыль: | INR142.21B (63.28 %) |
EPS: | INR34.72 |
FY | 2022 |
Выручка: | INR216.33B |
Валовая прибыль: | INR124.03B (57.33 %) |
EPS: | INR31.20 |
FY | 2021 |
Выручка: | INR190.23B |
Валовая прибыль: | INR110.03B (57.84 %) |
EPS: | INR29.82 |
Financial Reports:
No articles found.
Cipla Limited Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
INR5.00 (N/A) |
INR0 (N/A) |
INR0 (N/A) |
INR0 (N/A) |
INR8.50 (N/A) |
INR0 (N/A) |
INR0 (N/A) |
INR0 (N/A) |
INR0 (N/A) |
INR0 (N/A) |
Very Unsafe
High risk of being cut
Unsafe
Heightened risk of being cut
Borderline
Moderate risk of being cut
Safe
Unlikely to be cut
Very Safe
Very unlikely to be cut
First Dividend | INR0.0933 | 1997-07-28 |
Last Dividend | INR8.50 | 2023-07-20 |
Next Dividend | INR0 | N/A |
Payout Date | 0000-00-00 | |
Next Payout Date | N/A | |
# dividends | 28 | -- |
Total Paid Out | INR55.50 | -- |
Avg. Dividend % Per Year | 0.41% | -- |
Score | 1.86 | -- |
Div. Sustainability Score | 3.06 | |
Div.Growth Potential Score | 3.02 | |
Div. Directional Score | 3.04 | -- |
Year | Amount | Yield |
---|---|---|
1997 | INR0 | 0.00% |
1998 | INR0 | 0.00% |
1999 | INR0 | 0.00% |
2000 | INR0 | 0.00% |
2001 | INR0 | 0.00% |
2002 | INR0 | 0.00% |
2003 | INR0 | 0.00% |
2004 | INR0 | 0.00% |
2005 | INR0 | 0.00% |
2006 | INR0 | 0.00% |
2007 | INR0 | 0.00% |
2008 | INR0 | 0.00% |
2009 | INR0 | 0.00% |
2010 | INR0 | 0.00% |
2011 | INR0 | 0.00% |
2012 | INR0 | 0.00% |
2013 | INR0 | 0.00% |
2014 | INR0 | 0.00% |
2015 | INR0 | 0.00% |
2016 | INR0 | 0.00% |
2017 | INR0 | 0.00% |
2018 | INR3.00 | 0.51% |
2019 | INR3.00 | 0.57% |
2020 | INR1.000 | 0.21% |
2021 | INR5.00 | 0.61% |
2022 | INR5.00 | 0.54% |
2023 | INR8.50 | 0.79% |
2024 | INR0 | 0.00% |
The company's low Dividend Sustainability Score (DSS) highlights potential challenges in upholding its current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. In conclusion, a more vigilant stance is recommended given the company's tentative dividend landscape.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
SHYAMMETL.NS | Dividend Junior | 2023-06-05 | Semi-Annually | 4 | 0.70% | |
MAXHEALTH.NS | Dividend Junior | 2023-09-08 | Insufficient data to determine frequency | 2 | 0.07% | |
GSPL.NS | Dividend Junior | 2023-09-01 | Annually | 19 | 0.81% | |
BANKINDIA.NS | Dividend Junior | 2023-06-20 | Sporadic | 23 | 1.34% | |
PRAJIND.NS | Dividend Junior | 2023-07-19 | Annually | 22 | 0.83% | |
KABRAEXTRU.NS | Dividend Junior | 2023-07-13 | Annually | 23 | 0.83% | |
DVL.NS | Dividend Junior | 2023-09-13 | Annually | 17 | 1.37% | |
ADANIENT.NS | Dividend Junior | 2023-07-06 | Annually | 23 | 0.08% | |
STARPAPER.NS | Dividend Junior | 2023-09-15 | Sporadic | 22 | 1.19% | |
MUNJALAU.NS | Dividend Junior | 2023-08-24 | Sporadic | 19 | 1.47% |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | 0.148 | 1.500 | 7.04 | 10.00 | [0 - 0.5] |
returnOnAssetsTTM | 0 | 1.200 | 0 | 0 | [0 - 0.3] |
returnOnEquityTTM | 0.153 | 1.500 | 9.41 | 10.00 | [0.1 - 1] |
payoutRatioTTM | 0 | -1.000 | 0 | 0 | [0 - 1] |
currentRatioTTM | 0 | 0.800 | -5.00 | -4.00 | [1 - 3] |
quickRatioTTM | 0 | 0.800 | -4.71 | -3.76 | [0.8 - 2.5] |
cashRatioTTM | 0 | 1.500 | -1.111 | -1.667 | [0.2 - 2] |
debtRatioTTM | 0 | -1.500 | 0 | 0 | [0 - 0.6] |
interestCoverageTTM | 51.90 | 1.000 | 10.00 | 10.00 | [3 - 30] |
operatingCashFlowPerShareTTM | 19.38 | 2.00 | 3.54 | 7.08 | [0 - 30] |
freeCashFlowPerShareTTM | 19.38 | 2.00 | 0.312 | 0.623 | [0 - 20] |
debtEquityRatioTTM | 0 | -1.500 | 0 | 0 | [0 - 2.5] |
grossProfitMarginTTM | 0.647 | 1.000 | 2.55 | 2.55 | [0.2 - 0.8] |
operatingProfitMarginTTM | 0.221 | 1.000 | 7.58 | 7.58 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | 0 | 1.000 | -1.111 | -1.111 | [0.2 - 2] |
assetTurnoverTTM | 0 | 0.800 | -3.33 | -2.67 | [0.5 - 2] |
Total Score | 3.06 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | 30.74 | 1.000 | 7.00 | 0 | [1 - 100] |
returnOnEquityTTM | 0.153 | 2.50 | 9.62 | 10.00 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | 19.38 | 2.00 | 3.54 | 0.623 | [0 - 30] |
dividendYielPercentageTTM | 0.602 | 1.500 | 10.00 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | 19.38 | 2.00 | 3.54 | 7.08 | [0 - 30] |
payoutRatioTTM | 0 | 1.500 | 0 | 0 | [0 - 1] |
pegRatioTTM | -3.05 | 1.500 | -10.00 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | 0.0625 | 1.000 | -0.937 | 0 | [0.1 - 0.5] |
Total Score | 3.02 |
Cipla Limited
Cipla Limited, together with its subsidiaries, manufactures and sells pharmaceutical products in India, the United States, South Africa, and internationally. The company offers active pharmaceutical ingredients; and formulations in various therapeutic areas, such as MI, angina, heart failure, hypertension, arrhythmia, lipid abnormalities and diabetes, obesity, HIV, respiratory, urology, oncology, cardio-metabolism, child health, infectious diseases and critical care, hepatitis, women's health, ophthalmology, and neuro psychiatry. It also provides respiratory products, including inhalers and nasal sprays, as well as other respiratory products consists of injectables and biosimilars. Cipla Limited has a licensing agreement with Merck & Co., Inc. for the manufacturing and distribution of Molnupiravir, an investigational oral antiviral drug; a license agreement with Eli Lilly and Company for the manufacture and commercialization of the drug baricitinib for Covid-19 indication; and collaborations with Dr. Reddy's Laboratories Ltd, Sun Pharmaceutical Industries Limited, Emcure Pharmaceuticals Limited, and Torrent Pharmaceuticals Limited for the clinical trial of the investigational oral anti-viral drug Molnupiravir. The company was incorporated in 1935 and is headquartered in Mumbai, India.
О Торговые сигналы
Данные торговые сигналы, представленные на этой странице, помогают определить, когда следует ПОКУПАТЬ или ПРОДАВАТЬ NA. Сигналы имеют задержку более 1 минуты. Пожалуйста, примите во внимание, что существует вероятность ошибки или неточностей в силу различных микро и макро факторов влияющих на фондовые рынки.
Данные тор“о”ые сигна“ы не являются определен“ыми, и getagraph.com не несет ответственности за какие-либо действия, предпринятые в от“ошении этих сигналов, как описано в Terms of Use. Сигналы основаны на широком спектре индикаторов технического анализа